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Abstract
Anti-inflammatory signals play an essential role in constraining the magnitude of an inflammatory response. Extracellular
adenosine is a critical tissue-protective factor, limiting the extent of inflammation. Given the potent anti-inflammatory
effects of extracellular adenosine, we sought to investigate how extracellular adenosine regulates T cell activation and
differentiation. Adenosine receptor activation by a pan adenosine-receptor agonist enhanced the abundance of murine
regulatory T cells (Tregs), a cell type critical in constraining inflammation. Gene expression studies in both naı ¨ve CD4 T cells
and Tregs revealed that these cells expressed multiple adenosine receptors. Based on recent studies implicating the
Adora2b in endogenous anti-inflammatory responses during acute inflammation, we used a pharmacologic approach to
specifically activate Adora2b. Indeed, these studies revealed robust enhancement of Treg differentiation in wild-type mice,
but not in Adora2b
2/2 T cells. Finally, when we subjected Adora2b-deficient mice to endotoxin-induced pulmonary
inflammation, we found that these mice experienced more severe inflammation, characterized by increased cell recruitment
and increased fluid leakage into the airways. Notably, Adora2b-deficient mice failed to induce Tregs after endotoxin-induced
inflammation and instead had an enhanced recruitment of pro-inflammatory effector T cells. In total, these data indicate
that the Adora2b adenosine receptor serves a potent anti-inflammatory role, functioning at least in part through the
enhancement of Tregs, to limit inflammation.
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Introduction
Inflammation in response to tissue injury is a carefully
orchestrated process, and insufficient or overexuberant inflamma-
tion can have catastrophic effects. One major pathway by which
inflammation and tissue homeostasis is regulated is through the
generation of extracellular adenosine, which can serve as a highly
effective ‘‘safety’’ signal [1]. In healthy individuals, extracellular
adenosine levels are low. During tissue injury and inflammation,
however, extracellular adenosine levels significantly increase due
to: 1) ATP release from activated and dead/dying cells, followed
by 2) generation of adenosine from ATP, ADP, and AMP, a
process critically dependent on the enzyme CD73 [2,3]. The
appropriate generation and clearance of extracellular adenosine
are critical in limiting tissue pathology, with mice genetically
deficient either in the generation (CD73-deficient mice) or
clearance (adenosine deaminase, ADA-deficient mice) of extracel-
lular adenosine displaying profound pathologies due to inappro-
priate control of inflammation [3,4,5,6].
Extracellular adenosine mediates its biological effects through
four adenosine receptors (Adora) (Adora1, Adora2a, Adora2b,
Adora3), each with distinct expression patterns and different
genetic roles in regulating physiology and inflammation [7]. Based
on genetic studies, adenosine-dependent signaling can play a
critical role in limiting tissue damage [8,9,10,11]. Significantly, the
anti-inflammatory adenosine pathway is coordinately induced
following injury/inflammation, with both CD73 (the extracellular
adenosine-generating enzyme) and adenosine receptors (Adora2a,
Adora2b) simultaneously induced [12]. Furthermore, by screening
for the relative activities of multiple Adoras, studies have revealed
that Adora2b (also known as the A2B receptor) is a potent anti-
inflammatory receptor [9,10,11,13,14].
T cells are a major cell type of the adaptive immune system that
orchestrate the immune response. Within the T cell compartment,
regulatory T cells (Tregs) serve a critical function in restraining
inappropriate immune responses and inhibiting inflammation.
Tregs mediate these inhibitory effects by multiple mechanisms
depending on the tissue and nature of injury/inflammation (e.g.
production of the anti-inflammatory cytokines interleukin (IL)-10,
IL-35 and transforming growth factor (TGF)-b, generation of
extracellular adenosine, and cell-contact dependent mechanisms)
[15,16,17]. Notably, Tregs can limit immune responses to a
specific infection or insult (this specificity resulting from the unique
T cell receptor expressed by the Tregs in question) or Tregs can
have a more general, nonspecific inhibitory effect [18,19]. While
Tregs can achieve their fate either during development (natural
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induced Treg (iTreg) [20], both cells express the transcription
factor FoxP3, a critical molecular determinant essential for Treg
function [21]. Recent studies have shown that extracellular
adenosine is one factor that can enhance the differentiation and
function of Tregs, potentially through signaling through Adora2a
[22,23,24,25].
While many studies have focused on the role of Adora2a in
regulating T cell function, much less is known about the
contribution of Adora2b and its effects on T cell differentiation.
In this study, we directly investigated the Adora2b receptor as a
regulator of Treg differentiation. These studies reveal a previously
unappreciated role for Adora2b in promoting Tregs both in vitro
and in vivo, and identify a previously unappreciated mechanism
by which Adora2b might limit inflammation.
Results
A pan-adenosine receptor agonist enhances the
abundance of Tregs following in vitro stimulation of
primary mouse T cells
Given the potent anti-inflammatory effects mediated by
extracellular adenosine, we tested the effect of a general adenosine
receptor agonist (NECA) on the relative abundance of Tregs, an
anti-inflammatory subset of T cells, after in vitro stimulation of
primary murine T cells. Consistent with previous reports [24],
NECA stimulation enhanced the relative abundance of FoxP3
expressing Tregs in stimulated splenocyte cultures (Fig. 1A–B).
TGF-b is a potent inducer of FoxP3 expression and an inducer
of Tregs. Adenosine receptor stimulation further enhanced Tregs
differentiation in the presence of TGF-b (Fig. 1C–D). Tregs
present following adenosine receptor stimulation had comparable
expression relative to normal Tregs based on their cell surface
expression of three proteins expressed on Tregs, CD25, CD39 and
CD73 (Fig. 1E), indicating that adenosine receptor stimulation did
not perturb the general phenotype of Tregs after in vitro culture.
To define potential mechanisms by which adenosine receptor
engagement might enhance Treg abundance, we measured
relative expression levels of the four adenosine receptors in both
naı ¨ve CD4 T cells and Tregs. This analysis identified that both T
cell subsets expressed all four of the adenosine receptors, with
mRNA expression of Adora2a and FoxP3 upregulated in Tregs
relative to naı ¨ve CD4 T cells (Fig. 2).
An Adora2b-specific agonist enhances Treg abundance
in vitro following activation of murine T cells
Previous studies have implicated the Adora2a adenosine
receptor in promoting Treg abundance [24]. Given the expression
of the Adora2b receptor in both naı ¨ve T cells and Tregs, and the
accumulated evidence of an anti-inflammatory effect for Adora2b
in vivo, we directly tested the consequence of an Adora2b-specific
agonist (Bay60-6583) [13] on in vitro cultures of activated primary
murine T cells. While Bay60-6583 treatment of control Adora2b+/
+ splenocytes resulted in an increased frequency of Tregs after
three days of culture, this compound had no effect on Treg
abundance in Adora2b2/2 cultures (Fig. 3). These data identify
that an Adora2b-specific agonist is capable of enhancing Tregs in
vitro.
Adora2b-deficient mice fail to increase Tregs after
endotoxin-induced pulmonary inflammation
We next sought to investigate the in vivo consequence of
Adora2b deficiency on T cell populations during pulmonary
inflammation. Previous studies have revealed that Adora2b-
deficient mice have enhanced pulmonary inflammation, marked
by increased neutrophil infiltration, elevated levels of pro-
inflammatory cytokines (e.g. IL-6, TNF-a), and decreased levels
of the anti-inflammatory cytokine IL-10 [26]. Consistent with
these earlier studies, we found that lipopolysaccharide (LPS)
exposed Adora2b2/2 mice had increased cellularity in the airways
after LPS exposure and increased protein leakage into the airways
relative to wild-type controls (Fig. 4A–B), with pronounced
neutrophil infiltration (Fig. 4C). Given the ability of an Adora2b
agonist to enhance Tregs, we tested the relative change in Treg
abundance in Adora2b2/2 mice following LPS exposure. Notably,
Adora2b2/2 mice failed to induce an increase in Tregs in the lung
or the airway after LPS exposure (Fig. 4D, E). Conversely,
Adora2b2/2 mice had an increased infiltration of CD4 effector T
Figure 1. Adenosine receptor activation enhances the abun-
dance of Tregs following in vitro stimulation of primary mouse
T cells. (A) Adenosine receptor activation enhances the abundance of
Tregs following antibody-mediated stimulation of T cells (using anti-
CD3 antibody, 1 mg/mL combined with 10 ng/mL of IL-2, in the absence
of TGF-b). Samples were either untreated (+Vehicle) or treated with
10 mM of NECA (+NECA), a potent adenosine receptor agonist, analyzed
three days post-stimulation for the relative abundance of FoxP3-
expressing Tregs. The numbers present in the upper left-hand corner of
each flow cytometry plot indicate the percentage of cells that are
FoxP3+ as defined by the square gate. Background staining with an
isotype control antibody is indicated in the leftmost panel. (B)
Quantitation of FoxP3-expressing cells following either control (vehicle
treated, white bars) or NECA treated (black bars), with data indicating
mean +/2 SEM of triplicate cultures done in two separate experiments.
(C) Adenosine receptor activation enhances the abundance of Tregs
following antibody-mediated stimulation of T cells in the presence of
TGF-b, a known inducer of Tregs (using anti-CD3 antibody, 1 mg/mL
combined with 10 ng/mL of IL-2, combined with 0.75 ng/mL TGF-b),
showing flow cytometric analysis (C) and quantitation (D). The numbers
present in the upper left-hand corner of each flow cytometry plot
indicate the percentage of cells that are FoxP3+ as defined by the
square gate. Relative abundance of Tregs within cultures were defined
by flow cytometry, with Tregs defined as live, MHC class II negative,
CD82, CD4+ cells that express the transcription factor FoxP3. Data
indicate mean +/2 SEM of triplicate cultures, representative of two
independent experiments. (E) Tregs generated by TGF-b with NECA
(solid black line) relative to Tregs generated by TGF-b treatment alone
(indicated in gray) have a comparable cell surface expression of CD25,
CD39 and CD73. Results representative of results from three
independent cultures, done in two independent experiments. Statistical
analysis was performed using unpaired t test, with statistically
significant differences as indicated.
doi:10.1371/journal.pone.0032416.g001
Adora2b Promotes Tregs
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Adora2b2/2 was elevated relative to Adora2b+/+ controls (Fig. 4F).
The failure to increase Treg abundance, coupled with an
enhanced recruitment of CD4 effector T cells identifies Adora2b
as a critical regulator which influences the relative contribution of
anti-inflammatory Tregs to pro-inflammatory effector T cells
during inflammation.
Discussion
During acute inflammatory responses, the generation of
extracellular adenosine is an important feedback mechanism that
limits inflammation [1,8]. The stepwise generation of extracellular
adenosine by CD39 and CD73 from ATP is thought to limit
inflammation by at least two ways: i) through the enzymatic
degradation of extracellular ATP, which can promote inflamma-
tion [27] and ii) by extracellular adenosine directly signaling
through adenosine receptors [1]. Notably, signaling through
adenosine receptors triggers multiple anti-inflammatory pathways
including the induction of IL-10 [28], the impaired immunoge-
nicity of dendritic cells [29], and the deneddylation of cullin-1 to
limit NF-kB activation [30]. In this manuscript, we present data
for a new anti-inflammatory mechanism downstream of Adora2b:
Adora2b-dependent induction of regulatory T cells.
The potent anti-inflammatory effects of Adora2b during acute
inflammation have been revealed in multiple studies of acute
inflammatory insults including studies of localized or systemic
microbial challenge [11,14,31,32,33]. Adora2b also has a
pronounced anti-inflammatory role in the context of ischemic
tissue injury (i.e. transient tissue hypoxia) such that Adora2b-
deficient mice have more severe acute ischemic injury in studies of
both renal and myocardial ischemia [9,10]. Notably, hypoxia
elicits multiple adaptive responses within cells to deal with limited
oxygen availability, including induction of the extracellular
adenosine sensing pathway [12,34,35], induction of toll-like
receptors TLR2 and TLR6 [36], activation of the NF-kB
machinery [37], and upregulation of integrins which modulate
cell trafficking [38]. Given the integration of hypoxic sensing
machinery with Adora2b, future studies will focus on how hypoxia
and extracellular adenosine signaling intersect in regulating the
generation of Tregs. This work is especially relevant given our
recent studies demonstrating that hypoxia can enhance the
generation of Tregs, thereby restricting hypoxia-associated
inflammation (Clambey et al, submitted).
While Adora2b signaling can be tissue protective, Adora2b can
also inappropriately restrict inflammation. This balance between
tissue-protection versus host-defense has been nicely revealed by
studies of cecal ligation and puncture, in which Adora2b-deficient
mice were more resistant to sepsis and sepsis-associated mortality
[33]. Furthermore, Belikoff et al found that an Adora2b antagonist
was capable of increasing survival in septic mice, even those, that
based on increased levels of IL-6 in the blood, were predicted to
succumb to mortality [33].
In contrast to the potential beneficial effects of Adora2b in acute
inflammatory contexts, this receptor can be detrimental in
conditions of prolonged inflammation [39,40,41]. For example,
in elegant studies from the Blackburn laboratory, the pulmonary
inflammation and fibrosis observed in adenosine deaminase (ADA)
deficient mice is significantly improved upon treatment of these
mice with an Adora2b-specific antagonist [39]. Surprisingly,
however, Adora2b genetic deficiency worsened ADA-deficient
inflammation [42]. This apparent discrepancy in the role of
Adora2b is likely due to the kinetics of Adora2b loss-of-function,
where pharmacological studies focused on the effects of blocking
Figure 2. Relative expression levels of adenosine receptor
genes in T cell subsets. Real-time PCR analysis of mRNA for the four
adenosine receptor genes in FACS purified CD4 T cell subsets of naı ¨ve
CD4 T cells or Tregs, with Tregs isolated from FoxP3GFP or DEREG mice.
Values were standardized to bulk spleen mRNA, with each value
showing expression relative to actin. High level expression of FoxP3
mRNA is consistent with a highly purified population of Tregs. Data
representative of two to three independent experiments, analyzing at
least three independently isolated populations for both naı ¨ve CD4 T
cells and Tregs. Data depict mean 6 SEM for each transcript. Statistically
significant differences were calculated by unpaired t test comparing
expression in naı ¨ve CD4 T cells relative to Tregs, as indicated.
doi:10.1371/journal.pone.0032416.g002
Figure 3. An Adora2b-specific agonist enhances Treg abun-
dance in vitro following activation of murine T cells. Bulk
splenocytes from either Adora2b+/+ (C57BL/6J) or Adora2b2/2 mice
were cultured with soluble anti-CD3 for three days with or without the
Bay60-6583 compound, at which time the relative abundance of Tregs
was assessed. (A) Fold change in Treg abundance relative to Adora2b+/
+ cultures without the Bay compound control, where Tregs were
defined as viable, CD4+ FoxP3+ cells by flow cytometry. (B) Flow
cytometry plots shown from Adora2b+/+ cultured splenocytes. Bay60-
6583, an Adora2b-specific agonist was added to a final concentration of
4 nM. Data from two independent experiments, each containing 1–3
independent replicates. The numbers present on each flow cytometry
plot indicate the percentage of cells that are FoxP3+ as defined by the
square gate, with FoxP3 expressing cells defined relative to isotype
control-stained samples (not shown). Statistically significant differences
are indicated and were calculated by one-way ANOVA followed by
Bonferroni’s post-test correction. ns indicates a comparison that is not
statistically significantly different.
doi:10.1371/journal.pone.0032416.g003
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ablation of Adora2b that occurred prior to the induction of
inflammation [42]. Consistent with this idea, direct comparison of
acute and chronic models of bleomycin-induced lung injury
demonstrated that while Adora2b served a potent anti-inflamma-
tory role during acute lung injury, Adora2b had little effect on
inflammation and was instead pro-fibrotic during chronic
pulmonary fibrosis [43]. The pathogenic potential of Adora2b in
chronic inflammation is not restricted to the lung. For example,
Adora2b signaling was recently revealed to be detrimental in sickle
cell anemia, a context in which elevated levels of extracellular
adenosine-Adora2b signaling promotes red blood cell sickling,
contributing to the pathogenesis of this disease [44].
Based on our current observations that Adora2b enhances
Tregs, it is interesting to speculate that some of the detrimental
effects of Adora2b in chronic pathologies may be due to excessive
generation or function of Tregs. A detrimental role for an
adenosine-driven Treg pathway may be particularly relevant in
the context of elevated extracellular adenosine levels (e.g. in
pulmonary fibrosis, sickle cell anemia, fibrosis or solid tumors
[5,44,45,46]). In fact, recent data indicate that Tregs may
participate in the process of fibrosis [47,48], with a pro-fibrotic
outcome occurring through increased Treg production of TGF-b1
and subsequent collagen production following immune activation
[49].
The divergent effects of Adora2b in acute and chronic
inflammatory contexts indicate that Adora2b function is likely to
be shaped by the cells and environments in which inflammation is
occurring. Our data define a role for Adora2b in enhancing Tregs
either in primary activated murine T cell cultures or after LPS
exposure, a finding consistent with a recent report showing that
antagonizing Adora2b signaling inhibits the generation of Tregs in
vitro [50]. In contrast to our findings, however, a recent paper
reported that Adora2b promoted the generation of pro-inflam-
Figure 4. Adora2b-deficient mice have increased inflammation with impaired induction of Tregs after LPS-induced lung injury. LPS-
induced inflammation was initiated in 9–12 wk-old male Adora2b+/+ (C57BL/6J) or age and weight matched Adora2b2/2 mice by intratracheal
instillation of LPS or saline. Bronchoalveolar lavage (BAL) fluids were collected 1 d post treatment. A) Leukocyte cell counts of BAL fluid were
determined utilizing a cellometer (mean 6 SEM, n=2–4). B) Protein content of BAL fluid was determined with BCA assay. Fold increase of protein
concentration in LPS treated BAL samples over respective saline BAL samples is displayed (mean 6 SEM, n=3–10). C) Analysis of cell infiltration into
the lung airspace (BAL) of mice exposed to inhaled LPS. Mice (Adora2b+/+ or Adora2b2/2) were exposed to nebulized saline or lipopolysaccharide
(LPS); 24 hours post-exposure, mice were euthanized, and BAL was harvested. Cells were then subjected to flow cytometric analysis to identify
neutrophils (highly granular, Gr1+ cells). D) Analysis of FoxP3 gene expression in lungs of mice exposed to inhaled LPS. Mice (Adora2b+/+ or 2/2)
were exposed to nebulized saline or lipopolysaccharide (LPS); 24 hours post-exposure, mice were euthanized, and perfused lungs were harvested.
Total RNA was harvested from lungs, cDNA prepared and analyzed by real-time PCR. Data depict mean (6 SEM) fold changes in indicated genes. Fold
change was calculated based on primer efficiencies, standardized to changes in actin, with Adora2b+/+ Saline mean value defined as 1. E) Fold
change in cell number of either regulatory T cells (lymphocyte size, CD3+ CD4+ FoxP3+) in the lung airspace (BAL) of mice exposed to inhaled saline
or LPS as above. Data are from 2–6 mice; 2 independent experiments. F) Relative abundance of CD4 effector T cells (Teffs, defined as lymphocyte size,
CD3+ CD4+ CD44high cells) to Tregs based on cell counts from either Adora2b+/+ or Adora2b2/2 mice, with pie charts depicting mean cell count for
the indicated cell populations from 2–6 mice; 2 independent expts. Analysis of total cellular infiltration into airways and protein leakage (panels A–B)
was done in animals treated with intratracheal LPS. Analysis of neutrophil infiltration and Tregs (panels C–F) was done in animals treated with inhaled
LPS. Statistically significant differences are indicated and were calculated either by one-way ANOVA (A) or by unpaired t test (B–E) with a focus on
whether Adora2b2/2 LPS treated animals were statistically different from either saline treated or Adora2b+/+ LPS treated mice.
doi:10.1371/journal.pone.0032416.g004
Adora2b Promotes Tregs
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discrepancy remains to be elucidated, it is notable that the Th17-
promoting effects of Adora2b in these studies were isolated to
effects of Adora2b specifically on dendritic cells, and not on
macrophages [51]. This observation raises the possibility that the
contribution of Adora2b to T cell differentiation depends on the
type of antigen presenting cell (e.g. dendritic cell versus
macrophage) and microenvironment. For example, while treat-
ment of dendritic cells with NECA induces IL-6 expression in an
Adora2b-dependent mechanism [51], Adora2b-deficient mice or
macrophages had increased levels of IL-6 during acute inflam-
mation, indicating that Adora2b can limit IL-6 in certain contexts
[26,33]. This cell-type specific regulation of IL-6 by Adora2b is
particularly relevant to understanding how Adora2b could either
induce anti-inflammatory Tregs, as we show here, or pro-
inflammatory Th17 cells [51], given that Treg differentiation
can be diverted to Th17 differentiation in the presence of IL-6
[52]. It will be important for future studies to elucidate the cell-
type specific contributions of Adora2b in controlling both acute
and chronic inflammatory responses.
The central role of Adora2b in determining the outcome of both
acute and chronic pathologies identifies this molecule as a
promising point of intervention. Since Adora2b serves as a
receptor both for extracellular adenosine as well as for alternative
ligands (e.g. Netrin-1, [53,54,55]), this receptor may function to
integrate multiple extrinsic cues to promote Tregs to restrict the
duration and magnitude of inflammation. Pharmacologic targeting
of adenosine pathways such as Adora2b may also synergize with
modalities that activate the hypoxic response and have been
shown to be tissue-protective in models of colitis [56,57].
Conversely, since both Adora2a and Adora2b signaling promote
Tregs, transient depletion of extracellular adenosine through the
administration of pegylated-ADA may be a potent method to
transiently limit the generation or activity of Tregs. Based on the
potential of Adora2b-targeted treatments to modulate regulatory
T cells, future studies will interrogate the consequences and
therapeutic benefits of manipulating the Adora2b-Treg axis in
both acute and chronic states of inflammation.
Methods
Mice
Adora2b+/+ (C57BL/6J) and Adora2b2/2 [13] mice were bred
in house. B6.Cg-Foxp3
tm2Tch/J (here referred to as FoxP3GFP [58])
were obtained from Jax and DEREG mice were kindly provided
by Dr. Tim Sparwasser [59]. All mouse experiments were done
using age- and sex-matched mice, with mice typically used
between 8–12 weeks of age. The animal protocol was approved by
the Institutional Animal Care and Use Committee of the
University of Colorado Denver (under Animal Welfare Assurance
Policy A3269-01, IACUC protocol B83708(07)1D) and is in
accordance with the National Institutes of Health guidelines for
use of live animals. The University of Colorado Denver, Anschutz
Medical Campus is accredited by the American Association for
Accreditation of Laboratory Animal Care (#00235).
Tissue harvest
At time of harvest, bronchoalveolar lavage (BAL) was harvested
by performing three sequential lavages of the airways, using an ice-
cold PBS solution containing 5 mM EDTA. Lungs were harvested
from mice, following perfusion of the lungs using saline. For lungs
subjected to flow cytometric analysis, lung tissue was mechanically
disrupted by scissors, followed by a one-hour incubation of lung
tissue with collagenase D at a final concentration of 1 mg/mL at
37 C. Following collagenase treatment, lung material was placed
over a 100 micron mesh and cells were forced through using the
plunger of a 3 mL syringe and multiple washes of disrupted
material.
T cell purification
T cells were purified from the spleen of mice, mechanically
disrupted over a 100 micron filter, subjected to magnetic bead
enrichment for CD4 T cells using a CD4 T cell isolation kit
(Miltenyi Biotec, Germany). Enriched CD4 T cells were then
subjected to FACS purification on a FACSAria (BD), with naı ¨ve
CD4 T cells purified based on the cell surface phenotype CD4+
CD62L
high CD44
low. FoxP3-expressing Tregs were purified from
two different genetically engineered mice which express GFP
specifically in Tregs, the FoxP3GFP (B6.Cg-Foxp3
tm2Tch/J from Jax
[58,60]) and DEREG mice (kindly provided by Dr. Tim
Sparwasser [59]). In both strains of mice, GFP expression is
directly linked to the regulatory sequences from the FoxP3 locus,
either using an internal ribosome entry site at the end of the
endogenous FoxP3 gene (in FoxP3GFP mice) or using a bacterial
artificial chromosome-based transgenic in which GFP was placed
downstream of the FoxP3 promoter (in DEREG mice). FoxP3
expressing cells were purified for subsequent qPCR analysis, with
Tregs identified and isolated by sorting as CD4+ GFP+ [58,60].
In vitro T cell cultures
Bulk splenocytes or purified CD4 T cells were cultured in
Iscove’s modified Dulbeco’s medium (IMDM, Gibco) containing
5% FBS, L-glutamine, penicillin/streptomycin and b-mercapto-
ethanol (50 mM). All cultures were done using cells at a
concentration of 1610
6 cells/mL. For cultures subjected to T cell
receptor stimulation, bulk splenocytes were stimulated with 1 mg/mL
soluble anti-CD3e (clone 145-2C11, eBioscience), supplemented with
10 ng/mL of recombinant mouse IL-2 (eBioscience). In vitro Treg
differentiation assays were done for 3 days. In certain assays,
exogenous TGF-b was added to the culture, using recombinant
human TGF-b1 (eBioscience). For assays in which cells were
stimulated with a pan receptor agonist, cultures were treated with
10 mM NECA (59-N-Ethylcarboxamidoadenosine, Tocris Biosci-
ence, MO, USA) for the duration of the culture. For cultures
stimulated with the Adora2b-specific agonist Bay60-6583, cultures
were treated with 4 nM Bay60-6583 (obtained from Bayer,
Germany).
RNA isolation and Real-time PCR
Total RNA was extracted from cells or tissue by Trizol, followed
by cDNA synthesis using iScript cDNA Synthesis Kit (Bio-Rad
Laboratories, Inc, Munich, Germany) according to the manufac-
turer’s instructions. Quantitative real-time reverse transcriptase
PCR (qPCR) (iCycler; Bio-Rad Laboratories, Inc.) was performed
to measure relative mRNA levels for various transcripts, with
qPCR master mix contained 1 mM sense and 1 mM antisense
primers with iQ
TM SYBRH Green (Bio-Rad Laboratories, Inc.).
For every assay, melt curve analysis was performed and samples
with aberrant melt curves were discarded. All qPCR assays were
standardized relative to b-actin levels.
Antibodies and Flow cytometric analysis
Antibodies were purchased from eBioscience unless otherwise
noted. Anti-mouse antibodies included CD4 (GK1.5), CD25
(PC61.5), CD39 (24DMS1), CD73 (eBioTY/11.8 (TY/11.8)),
FoxP3 (FJK-16s), Gr1 (RB6-8C5), and MHC class II (M5/
114.15.2). Single cell suspensions of cultured cells or disrupted
Adora2b Promotes Tregs
PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e32416tissue were stained with a cocktail of antibodies for 30 minutes at
room temperature in the dark, in staining buffer containing an
anti-Fc receptor antibody (2.4G2). When cells were stained for
FoxP3, staining was done using FoxP3 staining buffer according to
manufacturer’s instructions (eBioscience). Unless stated otherwise,
all stains included a viability dye to identify viable cells (LIVE/
DEADH Fixable Aqua Dead Cell Stain Kit, Invitrogen), with
Tregs routinely identified as lymphocytes (based on forward and
side scatter profiles) that were viable, MHC class II negative cells,
which expressed CD4 and FoxP3. FoxP3-expressing Tregs were
identified by comparing fluorescent signal between samples stained
with an isotype control antibody (background staining), relative to
samples stained with a FoxP3-specific antibody. Isotype stained
controls routinely had less than 0.5% positive events within the
FoxP3+ gate. All flow cytometry was done on an LSRII (BD), with
compensation done using FACSDiva software. All flow cytometry
data is show on a log10 scale.
Primers for qPCR analysis
All primers used for qPCR are indicated below, with a 59 to 39
orientation, and m referring to mouse. mbeta-actin: Fwd-
CTAGGCACCAGGGTGTGAT, Rev-TGCCAGATCTTCTC-
CATGTC; mFoxP3: Fwd-TCTCCAGGTTGCTCAAAGTC, Rev-
GCAGAAGTTGCTGCTTTAGG; mAdora1: Fwd-AGAACCA-
CCTCCACCCTTCT, Rev-TACTCTGGGTGGTGGTCACA;
mAdora2a: Fwd-GAAGCAGATGGAGAGCCAAC, Rev-GAGA-
GGATGATGGCCAGGTA; mAdora2b: Fwd-TGCATGCCAT-
CAACTGTATC, Rev-TGGAAACTGTAGCGGAAGTC; mA-
dora3: Fwd-TCCCTGATTACCACGGACTC, Rev-CAATTCGC-
TCCTTCTGTTCC.
Murine LPS exposure models
Male Adora2b+/+ (C57BL/6J mice, The Jackson Laboratory,
ME) and Adora2b2/2 on a C57BL/6J background were
randomly assigned to saline or LPS treatment groups at age 9–
12 wk. LPS from Escherichia coli 0111:B4 (L4391, Sigma-Aldrich)
was dissolved in 0.9% saline (2 mg/mL). Animals were anesthe-
tized with pentobarbital (70 mg/kg i.p.). A volume of either 50 mL
LPS (100 mg/animal) or saline was instilled intratracheally via a
22-gauge canule, followed by 0.1 mL of air. Animals were
harvested 24 hours after instillation. For studies in which mice
were exposed to aerosolized LPS, mice were exposed to
aerosolized LPS in a cylindrical chamber connected to an air
nebulizer (MicroAir; Omron Healthcare, Mannheim, Germany)
as published previously [26].
Measurement of BAL fluid protein content
After collection samples were centrifuged for 1 min at 3,0006g,
and supernatant was stored at 280uC. Colorimetric Pierce
bicinchoninic acid (BCA) protein assay (Thermo Scientific) was
performed according to the manufacturer’s protocol to determine
protein content of BAL supernatant.
Leukocyte counts of BAL fluid
BAL samples were mixed gently prior to diluting 50 mL of BAL
fluid with 50 ml of Trypan blue (1:5 in 16 PBS) for viable cell
counts. 20 ml of diluted cell sample were pipetted on a cellometer
cell counting chamber. Leukocytes were automatically counted
using a Cellometer Auto T4 (Nexcelom Bioscience, Lawrence,
MA, USA).
Software & statistical analysis
Data analysis and plotting were done using Prism 4.0c
(GraphPad Software, Inc, San Diego, CA). Flow cytometric data
were analyzed using FlowJo (TreeStar, Inc, Ashland, OR), with
data displayed as high-resolution zebra plots showing outliers,
using log10 scales. Statistical analyses were performed using Prism
4.0c, with unpaired t-tests or one-way ANOVA and Bonferroni’s
multiple comparison post-test correction for all other analyses.
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